Leadership

Steven P. James

Executive Chairman and CEO

Michel Streuli, PhD

Senior Vice President, Research

Mike Ellis, PhD

Vice President, Business Operations

Sriram Venkataraman, PhD

Director, Immune-Pharmacology


Steven P. James

Executive Chairman and CEO

Steve has over 25 years of biopharma experience and has been involved in building and leading numerous companies. Prior to joining Pionyr in February 2016, he was president, CEO, and a director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president, CEO, and a director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceutials, Ionis Pharmaceuticals, Landec Corporation, and Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently a director of Ocera Inc., Cascadian Therapeutics, Antiva Biosciences, Allakos Inc., and Chrono Therapeutics and is a trustee of Middlebridge School in Rhode Island.

Michel Streuli, PhD

Senior Vice President, Research

Michel joined Pionyr Immunotherapeutics in 2016 to lead research. Prior to Pionyr, Dr. Streuli held senior research positions at Gilead, Merck, Schering-Plough, and Organon, following a decade on the faculties of the Dana-Farber Cancer Institute and Harvard Medical School. During his 16 years in the pharmaceutical and biotech industry, he has led numerous drug development programs from discovery through early clinical stage, with a focus on therapies for cancer, chronic viral, autoimmune and inflammatory diseases, including overseeing development of the immunomodulatory anti-PD-1 monoclonal antibody Keytruda, and chairing the Keytruda early development team that brought Keytruda to the clinic. Dr. Streuli holds a PhD degree from the University of Zurich, where he was involved in the cloning and characterization of interferon-alpha-2, which led to the development of INTRON A and PEG-INTRON.

Mike Ellis, PhD

Vice President, Business Operations

Mike joined Pionyr in 2017 and has over 20 years of experience in innovative biopharmaceutical companies, with expertise in business and corporate development, alliance management, research and clinical development. Prior to Pionyr, he was with Regeneron’s Strategic Alliances group, where he led Regeneron’s broad antibody discovery alliance with Sanofi and managed key aspects of Regeneron’s PD-1 program, which formed the foundation of the comprehensive Regeneron-Sanofi immuno-oncology alliance. He was also a key contributor to numerous preclinical and clinical stage antibody programs across a variety of therapeutic areas. He previously held senior positions in corporate development at Renovis, and in research at Renovis, Exelixis and Mercator Genetics. Mike holds an MBA from the Wharton School of Business and a PhD from the University of California, Berkeley.

Sriram Venkataraman, PhD

Director, Immune-Pharmacology

Sriram has over a decade of pharmaceutical research experience developing biological and small molecule therapeutics against tumor immunotherapy targets. Prior to joining Pionyr Immunotherapeutics in 2016, he led several immuno-oncology programs at Gilead Sciences and Merck. At Merck, Sriram also served as the cross-site preclinical pharmacology lead for all immuno-oncology programs, including the anti-PD-1 antibody Keytruda program. He received his PhD degree in Biochemistry and Immunology from the University of Madras, India, and did his post-doctoral training in immunology at the Indiana University School of Medicine.